NYSE:GKOS (USA) Also Trade In: Germany
Glaukos Corp $ 85.76 2.03 (2.42%)
Warning! GuruFocus has detected 3 Severe warning signs with GKOS. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for GKOS (Glaukos Corp) from 2015 to Mar 06 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Glaukos stock (GKOS) PE ratio as of Mar 06 2021 is 0. More Details
Glaukos PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Glaukos PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:STAA NYSE:CMD NAS:ATRC NAS:LMNX NAS:ATRI NAS:MMSI NAS:OSUR NAS:LMAT NAS:ATRS NAS:ANGO NYSE:BDX NAS:ISRG XPAR:EL NYSE:BAX OCSE:COLO B TSE:7741 XSWX:ALC TSE:4543 XPAR:DIM NYSE:RMD
Address 229 Avenida Fabricante, San Clemente, CA, USA, 92672
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.